Mendus AB is a clinical-level biopharmaceutical company, which engages in the provision of allogeneic dendritic cell biology focused on the development of immunotherapies that address tumor recurrence and hard-to-treat established tumors. It operates under the Sweden and Netherlands geographic segments. The company was founded by Bengt Anders Andersson, Alex Karlsson-Parra, and AnnaCarin Wallgren in 2002 and is headquartered in Stockholm, Sweden.